Influence on brain perfusion and metabolism through pharmacologic agents

Phase 2

Recruiting

• Conditions: multiple sclerosis; 10012303

• Registration Number: NL-OMON29781
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1) a diagnosis of MS, according to the McDonald criteria with a secondary progressive disease course and a disease duration of between ten and fifteen years
2) age 18-60 years
3) informed consent

Exclusion Criteria

1) use of systemic corticosteroids in the eight weeks before inclusion into the trial
2) use of immunomodulatory treatments for MS
3) a history of cerebral pathology other than MS (cerebral infarct, cerebral haemorrhage, Parkinson's disease, Alzheimer's disease, cerebral vasculitis, brain absces)
4) diabetes mellitus, cardiac arrhytmia, prolonged qt time on ecg, pregnancy or breast feeding.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- The difference in measures of cerebral perfusion before and after use of the<br /><br>trial medication in and between the groups of patients and healthy control<br /><br>persons<br /><br>- The difference in measures of cerebral metabolism (as measured with MR<br /><br>spectroscopy) in and between the groups of patients and healthy control persons</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>none</p><br>